| Notices |
Welcome to the Wound Management Forum forums, for communication between health professionals about wound care and management and related topics.
You are currently viewing our wound management forum as a guest which gives you limited access to view all discussions and access our other features. By joining our free global community you will have access to post wound management topics and reviews (as well as answer and ask questions), communicate privately with other members (PM), upload content, view attachments, receive a weekly email update of new discussions, access many other special features. Registered users do not get displayed the advertisments in posted messages. Registration is fast, simple and absolutely free so please, join our global wound management community today!
If you have any problems with the registration process or your account login, please contact contact us. |
 |
29th May 2009, 10:15 PM
|
#1
|
|
Administrator
Join Date: Jun 2008
Posts: 11,641
Thanks: 0
Thanked 0 Times in 0 Posts
|
Pivotal Trial of Dermagraft(R) to Treat Venous Leg Ulcers (DEVO)
Pivotal Trial of Dermagraft(R) to Treat Venous Leg Ulcers (DEVO)
Quote:
This study randomly assigns patients with venous leg ulcers to receive standard therapy (compression) alone or compression plus Dermagraft(R).
Dermagraft is a device containing live human fibroblasts grown on an absorbable Vicryl mesh. Patients are seen weekly until they heal or the 16-week treatment period is complete. Follow-up visits are conducted monthly for three months in order to assess patients for longer term safety.
|
|
|
|
| Thread Tools |
|
|
| Display Modes |
 Linear Mode
|
Posting Rules
|
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts
HTML code is Off
|
|
|
All times are GMT. The time now is 09:10 PM.
Powered by vBulletin® Version 3.7.1 Copyright ©2000 - 2013, Jelsoft Enterprises Ltd.
Wound Management Forum © Copyright 2008 All Rights Reserved. Content published on Wound Management Forum requires permission for reprint.
|
